SPORT-SPECIFIC HIIT IN ELITE KICKBOXERS
Condition(s) studied
Investigational drug(s) / intervention(s)
Sport-Specific High-Intensity Interval Training: Participants perform supervised sport-specific high-intensity interval training five days per week for eight weeks. Training intensity is maintained at approximately 85-95 percent of maximum heart rate. The program consists of repeated high-intensity exercise intervals interspersed with active recovery periods and is designed to reflect the physiological demands of competitive kickboxing.
Regular Training: Participants continue their usual kickboxing training routines without participation in the structured HIIT program.
Study summary
This study examines how sport-specific high-intensity interval training (HIIT) affects the body in elite kickboxers.
Participants are randomly assigned to either a HIIT training group or a control group. The HIIT group performs supervised sport-specific training for eight weeks, while the control group continues their usual training. Blood samples are collected before and after the training period.
The main goal of this study is to determine whether HIIT changes levels of exercise-related proteins such as apelin and irisin. These proteins may reflect how the body adapts to intense training.
The findings may help researchers and coaches better understand the effects of high-intensity training and may support the development of safer and more effective training programs for athletes.
Eligibility
Primary outcome measure(s)
- Serum Apelin Concentration — Baseline and Week 8
Serum apelin concentration measured using enzyme-linked immunosorbent assay (ELISA).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Adiyaman University Faculty of Sport Sciences | Adıyaman | Turkey (Türkiye) |
More Adiyaman University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07449663 on ClinicalTrials.gov ↗ ← All trials in Turkey